Exosome skin treatments show early promise but rest on thin, low-quality evidence
A scoping review of 17 human studies finds exosome therapies may improve skin aging and inflammation, but weak study designs and rare serious reactions warrant caution.
Résumé
Exosomes, tiny vesicles released by cells, are being marketed for skin rejuvenation, scarring, hair loss, and inflammatory skin disease. Lab studies suggest they can activate skin repair, but the human evidence has been unclear. This scoping review searched major databases, trial registries, and grey literature and found 17 human studies from 2020 to 2025. Most used exosomes from mesenchymal stem cells, applied topically, with microneedling, with fractional CO2 laser, or by injection. About 76% of studies reported improvements in wrinkles, pigmentation, elasticity, hydration, or scars. Adverse events were uncommon but included granulomas, tissue necrosis, and allergic reactions after injection. The authors conclude the therapies show promise, but small samples, short follow-up, non-randomized or single-arm designs, and possible conflicts of interest limit confidence in the results.
Résumé détaillé
Exosome products are already sold commercially for skin rejuvenation, even though their clinical evidence and safety profile have not been well defined. Pre-clinical work suggests exosomes can activate dermal repair pathways, which makes them attractive for aging, pigmentation, scarring, hair loss, and inflammatory skin conditions.
This scoping review followed PRISMA-ScR guidelines to map the human evidence. The authors searched MEDLINE, Embase, CENTRAL, PubMed, U.S. and E.U. trial registries, and grey literature, including only studies in human participants.
Seventeen studies published from 2020 to 2025 were included: cohort studies, comparative trials, and case series. Indications covered skin rejuvenation, psoriasis, acne scars, and atopic dermatitis. Exosomes were mostly derived from mesenchymal stem cells and delivered topically, via microneedling, with fractional CO2 laser, or by injection. Roughly 76% of studies reported improvement in wrinkles, pigmentation, elasticity, hydration, or scarring.
Safety reports were mixed. Adverse events were described as uncommon, but they included granulomas, necrosis, and allergic reactions following injection. These are clinically meaningful risks, particularly for products delivered into the skin.
The authors conclude that exosome therapies are promising for rejuvenation and inflammatory dermatoses, but the evidence base is weak. Samples were small, follow-up was short, and many designs were non-randomized or single-arm. Potential conflicts of interest further limit interpretation. Because only the abstract was available, details such as product standardization, effect sizes, and individual study quality could not be assessed. Clinicians and consumers should treat current claims cautiously until randomized, well-controlled trials and clearer regulatory standards emerge.
Principales conclusions
- Seventeen human studies from 2020-2025 were identified, mostly cohort studies, comparative trials, and case series.
- About 76% of studies reported improvements in wrinkles, pigmentation, elasticity, hydration, or scars.
- Most exosomes were mesenchymal stem cell-derived, given topically, with microneedling or fractional CO2 laser, or by injection.
- Reported adverse events were uncommon but included granulomas, necrosis, and allergic reactions after injection.
- Evidence is limited by small samples, short follow-up, non-randomized designs, and potential conflicts of interest.
Méthodologie
This was a scoping review conducted per PRISMA-ScR, searching MEDLINE, Embase, CENTRAL, PubMed, U.S. and E.U. trial registries, and grey literature. Only human studies were eligible, yielding 17 studies from 2020-2025. Findings were mapped and summarized rather than pooled or formally risk-of-bias graded, based on the abstract.
Limites de l'étude
Included studies were small, short in follow-up, and largely non-randomized or single-arm, with potential conflicts of interest. The 76% improvement figure reflects the share of studies reporting benefit, not effect size, and may be affected by publication bias. Only the abstract was reviewed, so product heterogeneity, dosing, and study quality details are unknown.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :